×

US FDA approves at-home use of BioXcel’s agitation drug

By Thomson Reuters Nov 16, 2026 | 8:19 AM

Nov 16 (Reuters) – The US Food and Drug Administration on Monday approved at-home use of BioXcel Therapeutics’ drug, Igalmi, ​for agitation associated with schizophrenia ‌or bipolar disorder.

The company last month completed the sale of nearly all its assets, including Igalmi, to a unit of Israel-based Teva Pharmaceuticals.

Here are ‌more ​details:

• The approval expands ⁠Igalmi’s use to outpatient ⁠settings without supervision of a healthcare provider, where there are no FDA-approved options available, Teva said

• Teva said it will ​announce commercialization plans for the drug’s at-home use at a later date

• ⁠Igalmi, chemically known as ⁠dexmedetomidine, was approved as an orally ​dissolving film in April 2022 to treat ​agitation associated with schizophrenia or bipolar disorder ‌in adults with medical supervision

• Schizophrenia is a mental health disorder that causes delusions, hallucinations and disorganized thinking. Bipolar disorder, ⁠also a mental health condition, causes strong mood swings

• Agitation associated with schizophrenia and bipolar disorder ⁠affects 25% ‌to 40% of patients across ⁠these conditions, Teva said

• Igalmi ​targets ‌brain receptors that help reduce stress-related ​behaviors such ⁠as agitation, a common symptom in patients with neurological disorders that causes physical or mental unease and excessive motor activity

(Reporting by Sneha S K in Bengaluru; Editing by ​Shreya Biswas)